The NEDD8 pathway is required for proteasome-mediated degradation of human estrogen receptor (ER)-alpha and essential for the antiproliferative activity of ICI 182,780 in ERalpha-positive breast cancer cells.
暂无分享,去创建一个
[1] J. Whitlock,et al. The aromatic hydrocarbon receptor, transcription, and endocrine aspects of dioxin action. , 2000, Vitamins and hormones.
[2] E. Yeh,et al. Identification of NEDD8-conjugation site in human cullin-2. , 1999, Biochemical and biophysical research communications.
[3] H. Suzuki,et al. NEDD8 recruits E2‐ubiquitin to SCF E3 ligase , 2001, The EMBO journal.
[4] Xiping Wang,et al. The COP9 Signalosome Inhibits p27kip1 Degradation and Impedes G1-S Phase Progression via Deneddylation of SCF Cul1 , 2002, Current Biology.
[5] R. Neve,et al. The Amyloid Precursor Protein-binding Protein APP-BP1 Drives the Cell Cycle through the S-M Checkpoint and Causes Apoptosis in Neurons* , 2000, The Journal of Biological Chemistry.
[6] K. Nephew,et al. Effect of Estradiol on Estrogen Receptor Expression in Rat Uterine Cell Types1 , 2000, Biology of reproduction.
[7] K. Nephew,et al. The activating enzyme of NEDD8 inhibits steroid receptor function. , 2002, Molecular endocrinology.
[8] S. Kaul,et al. Ubc9 Is a Novel Modulator of the Induction Properties of Glucocorticoid Receptors* , 2002, The Journal of Biological Chemistry.
[9] R. Casper,et al. Interaction with Nedd8, a Ubiquitin-like Protein, Enhances the Transcriptional Activity of the Aryl Hydrocarbon Receptor* , 2002, The Journal of Biological Chemistry.
[10] M. Parker,et al. Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[11] C. Schwechheimer,et al. Interactions of the COP9 Signalosome with the E3 Ubiquitin Ligase SCFTIR1 in Mediating Auxin Response , 2001, Science.
[12] E. Lightcap,et al. A Nedd8 conjugation pathway is essential for proteolytic targeting of p27Kip1 by ubiquitination. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[13] Angus Chen,et al. Conjugation of Nedd8 to CUL1 Enhances the Ability of the ROC1-CUL1 Complex to Promote Ubiquitin Polymerization* , 2000, The Journal of Biological Chemistry.
[14] H. Soule,et al. Estrogen receptor in a human cell line (MCF-7) from breast carcinoma. , 1973, The Journal of biological chemistry.
[15] S. Jentsch,et al. Conjugation of the ubiquitin-like protein NEDD8 to cullin-2 is linked to von Hippel-Lindau tumor suppressor function. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[16] V. Jordan,et al. MCF-7: the first hormone-responsive breast cancer cell line. , 1997, Cancer research.
[17] E. Yeh,et al. A Dominant-negative UBC12 Mutant Sequesters NEDD8 and Inhibits NEDD8 Conjugation in Vivo * , 2000, The Journal of Biological Chemistry.
[18] A. Bitonti,et al. Progression of MCF-7 breast cancer cells to antiestrogen-resistant phenotype is accompanied by elevated levels of AP-1 DNA-binding activity. , 1996, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[19] V. Chau,et al. Nedd8 Modification of Cul-1 Activates SCFβTrCP-Dependent Ubiquitination of IκBα , 2000, Molecular and Cellular Biology.
[20] A. Howell,et al. Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer. , 1996, British Journal of Cancer.
[21] B. O’Malley,et al. Proteasome-dependent degradation of the human estrogen receptor. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[22] J. Baxter,et al. The limits of the cellular capacity to mediate an estrogen response. , 1992, Molecular endocrinology.
[23] B. Katzenellenbogen,et al. Estrogen receptor synthesis and turnover in MCF-7 breast cancer cells measured by a density shift technique. , 1984, Endocrinology.
[24] A. Lykkesfeldt,et al. Anti-oestrogen resistant human breast cancer cell lines are more sensitive towards treatment with the vitamin D analogue EB1089 than parent MCF-7 cells , 2001, British Journal of Cancer.
[25] M. Goebl,et al. Modification of yeast Cdc53p by the ubiquitin-related protein rub1p affects function of the SCFCdc4 complex. , 1998, Genes & development.
[26] B. Keegan,et al. Inhibiting proteasomes in human HepG2 and LNCaP cells increases endogenous androgen receptor levels. , 2000, Biochemical and biophysical research communications.
[27] N. Weigel,et al. Polyglutamine-expanded androgen receptors form aggregates that sequester heat shock proteins, proteasome components and SRC-1, and are suppressed by the HDJ-2 chaperone. , 1999, Human molecular genetics.
[28] S. Hilsenbeck,et al. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. , 1995, Journal of the National Cancer Institute.
[29] W. Kaelin,et al. An intact NEDD8 pathway is required for Cullin‐dependent ubiquitylation in mammalian cells , 2002, EMBO reports.
[30] R. Deshaies. SCF and Cullin/Ring H2-based ubiquitin ligases. , 1999, Annual review of cell and developmental biology.
[31] P. Briand,et al. Human breast cancer cell lines resistant to pure anti‐estrogens are sensitive to tamoxifen treatment , 1995, International journal of cancer.
[32] G. Leclercq,et al. Implication of proteasome in estrogen receptor degradation , 1999, FEBS letters.
[33] A. Howell,et al. ICI 182,780 (Faslodex™) , 2000, Cancer.
[34] B. O’Malley,et al. FRAP reveals that mobility of oestrogen receptor-alpha is ligand- and proteasome-dependent. , 2001, Nature cell biology.
[35] Y. Xiong,et al. The CUL1 C-Terminal Sequence and ROC1 Are Required for Efficient Nuclear Accumulation, NEDD8 Modification, and Ubiquitin Ligase Activity of CUL1 , 2000, Molecular and Cellular Biology.
[37] R. Thampan,et al. Ubiquitination of the rat uterine estrogen receptor: dependence on estradiol. , 1995, Biochemical and biophysical research communications.
[38] M. Estelle,et al. The Arabidopsis cullin AtCUL1 is modified by the ubiquitin-related protein RUB1. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[39] D A Scudiero,et al. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. , 1988, Cancer research.
[40] E. Yeh,et al. Targeting of NEDD8 and Its Conjugates for Proteasomal Degradation by NUB1* , 2001, The Journal of Biological Chemistry.
[41] M. Lippman,et al. The effects of estrogens and antiestrogens on hormone-responsive human breast cancer in long-term tissue culture. , 1976, Cancer research.
[42] Z. Nawaz,et al. Importance of the regulation of nuclear receptor degradation. , 2001, Frontiers in bioscience : a journal and virtual library.
[43] A. Shevchenko,et al. Promotion of NEDD8-CUL1 Conjugate Cleavage by COP9 Signalosome , 2001, Science.
[44] O. Silvennoinen,et al. ARIP3 (androgen receptor-interacting protein 3) and other PIAS (protein inhibitor of activated STAT) proteins differ in their ability to modulate steroid receptor-dependent transcriptional activation. , 2000, Molecular endocrinology.
[45] J. Pink,et al. Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines. , 1996, Cancer research.
[46] J Lippman,et al. MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen. , 1997, Cancer research.
[47] The fission yeast COP9/signalosome is involved in cullin modification by ubiquitin-related Ned8p , 2001, BMC Biochemistry.
[48] Keiji Tanaka,et al. Covalent modification of all members of human cullin family proteins by NEDD8 , 1999, Oncogene.
[49] J. Palvimo,et al. Covalent modification of the androgen receptor by small ubiquitin-like modifier 1 (SUMO-1). , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[50] D. McDonnell,et al. The Human Estrogen Receptor-α Is a Ubiquitinated Protein Whose Stability Is Affected Differentially by Agonists, Antagonists, and Selective Estrogen Receptor Modulators* , 2001, The Journal of Biological Chemistry.
[51] C. Lange,et al. Phosphorylation of human progesterone receptors at serine-294 by mitogen-activated protein kinase signals their degradation by the 26S proteasome. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[52] O. Jänne,et al. Ubc9 Interacts with the Androgen Receptor and Activates Receptor-dependent Transcription* , 1999, The Journal of Biological Chemistry.
[53] R. Honda,et al. Modification of cullin-1 by ubiquitin-like protein Nedd8 enhances the activity of SCF(skp2) toward p27(kip1). , 2000, Biochemical and biophysical research communications.
[54] T. Toda,et al. Covalent modifier NEDD8 is essential for SCF ubiquitin‐ligase in fission yeast , 2000, The EMBO journal.
[55] E. Yeh,et al. Ubiquitin-like proteins: new wines in new bottles. , 2000, Gene.
[56] E. Yeh,et al. Identification of the Activating and Conjugating Enzymes of the NEDD8 Conjugation Pathway* , 1999, The Journal of Biological Chemistry.
[57] E. Alarid,et al. Proteasome-mediated proteolysis of estrogen receptor: a novel component in autologous down-regulation. , 1999, Molecular endocrinology.
[58] E. Yeh,et al. NUB1, a NEDD8-interacting Protein, Is Induced by Interferon and Down-regulates the NEDD8 Expression* , 2001, The Journal of Biological Chemistry.
[59] A. Ciechanover,et al. The NEDD8 Pathway Is Essential for SCFβ-TrCP-mediated Ubiquitination and Processing of the NF-κB Precursor p105* , 2002, The Journal of Biological Chemistry.
[60] B. O’Malley,et al. The 26S proteasome is required for estrogen receptor-alpha and coactivator turnover and for efficient estrogen receptor-alpha transactivation. , 2000, Molecular cell.
[61] N. McKenna,et al. Nuclear Receptors, Coregulators, Ligands, and Selective Receptor Modulators , 2001, Annals of the New York Academy of Sciences.
[62] C. Pickart,et al. Mechanisms underlying ubiquitination. , 2001, Annual review of biochemistry.